[go: up one dir, main page]

RU2002114345A - Новые 4-(пиперазинил(8-хинолинил)метил)бензамиды - Google Patents

Новые 4-(пиперазинил(8-хинолинил)метил)бензамиды

Info

Publication number
RU2002114345A
RU2002114345A RU2002114345/04A RU2002114345A RU2002114345A RU 2002114345 A RU2002114345 A RU 2002114345A RU 2002114345/04 A RU2002114345/04 A RU 2002114345/04A RU 2002114345 A RU2002114345 A RU 2002114345A RU 2002114345 A RU2002114345 A RU 2002114345A
Authority
RU
Russia
Prior art keywords
compound
methyl
quinolinyl
piperazinyl
diethyl
Prior art date
Application number
RU2002114345/04A
Other languages
English (en)
Other versions
RU2260006C2 (ru
Inventor
Уиль м БРАУН (CA)
Уильям БРАУН
Кристофер УОЛПОЛ (CA)
Кристофер Уолпол
Никлас ПЛОБЕК (CA)
Никлас ПЛОБЕК
Original Assignee
Астразенека Аб (Se)
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб (Se), Астразенека Аб filed Critical Астразенека Аб (Se)
Publication of RU2002114345A publication Critical patent/RU2002114345A/ru
Application granted granted Critical
Publication of RU2260006C2 publication Critical patent/RU2260006C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)

Claims (20)

1. Соединение формулы
Figure 00000001
где R1 выбран из (1) фенила;
(2)пиридинила
Figure 00000002
(3) тиофенила
Figure 00000003
(4) фуранила
Figure 00000004
(5) имидазолила
Figure 00000005
и
(6) триазолила
Figure 00000006
где каждое фенильное кольцо и гетероароматическое кольцо может быть возможно и независимо дополнительно замещено 1, 2 или 3 заместителями, выбранными из прямого и разветвленного С1-С6алкила, NO2, CF3, С1-С6алкокси, хлоро, фторо, бромо и йодо;
а также его фармацевтически приемлемые соли и его изомеры.
2. Соединение по п.1, где возможный(ые) заместитель(ли) на ароматическом или гетероароматическом кольце(ах) выбран(ы) любой из NO2, изобутила, CF3, метокси, метила или хлоро.
3. Соединение по п.1 или 2, выбранное из любого из
4-[(4-бензил-1-пиперазинил)(8-хинолинил)метил]-N,N-диэтилбензамида дигидрохлорида (соединение 2);
N,N-диэтил-4-[[4-(4-метилбензил)-1-пиперазинил](8-хинолинил)метил]бензамида (соединение 5);
4-[{4-[4-(трет-бутил)бензил]-1-пиперазинил}(8-хинолинил)метил]-N,N-диэтилбензамида дигидрохлорида (соединение 8);
N,N-диэтил-4-[[4-(4-нитробензил)-1-пиперазинил](8-хинолинил)метил]бензамида дигидрохлорида (соединение 9);
4-[{4-[2,4-бис(трифторметил)бензил]-1-пиперазинил}(8-хинолинил)метил]-N,N-диэтилбензамида дигидрохлорида (соединение 10);
N,N-диэтил-4-[[4-(4-метоксибензил)-1-пиперазинил](8-хинолинил)метил]бензамида дигидрохлорида (соединение 11);
4-[[4-(2,4-дихлорбензил)-1-пиперазинил](8-хинолинил)метил]-N,N-диэтилбензамида дигидрохлорида (соединение 12);
N,N-диэтил-4-[[4-(2-пиридинилметил)-1-пиперазинил](8-хинолинил)метил]бензамида дигидрохлорида (соединение 13);
N,N-диэтил-4-[[4-(3-тиенилметил)-1-пиперазинил](8-хинолинил)метил]бензамида (соединение 14);
N,N-диэтил-4-[[4-(2-фуранилметил)-1-пиперазинил](8-хинолинил)метил]бензамида (соединение 15);
N,N-диэтил-4-[[4-(3-фуранилметил)-1-пиперазинил](8-хинолинил)метил]бензамида (соединение 16);
N,N-диэтил-4-[[4-(2-тиофенилметил)-1-пиперазинил](8-хинолинил)метил]бензамида дигидрохлорида (соединение 17);
N,N-диэтил-4-[[4-(2-имидазолилметил)-1 -пиперазинил](8-хинолинил)метил]бензамида дигидрохлорида (соединение 18);
N,N-диэтил-4-[[4-(4-имидазолилметил)-1-пиперазинил](8-хинолинил)метил]бензамида дигидрохлорида (соединение 19) и
N,N-диэтил-4-[[4-(3-триазолилметил)-1-пиперазинил](8-хинолинил)метил]бензамида дигидрохлорида (соединение 20).
4. Соединение по любому из пп.1-3, которое находится в виде (+)-энантиомера.
5. Соединение по любому из пп.1-3, которое находится в виде (-)-энантиомера.
6. Соединение по любому из пп.1-5 в форме его солей гидрохлорида, сульфата, тартрата или цитрата.
7. Соединение по п.4, выбранное из любого из
(+)4-[(4-бензил-1-пиперазинил)(8-хинолинил)метил]-N,N-диэтилбензамида и
(+)4-[[4-(4-метилбензил-1-пиперазинил](8-хинолинил)метил]-N,N-диэтилбензамида.
8. Соединение по п.5, выбранное из любого из
(-)4-[(4-бензил-1-пиперазинил)(8-хинолинил)метил]-N,N-диэтилбензамида и
(-)4-[[4-(4-метилбензил-1-пиперазинил](8-хинолинил)метил]-N,N-диэтилбензамида.
9. Соединение по любому из пп.1-8 для применения в терапии.
10. Соединение по п.9, где терапия представляет собой устранение боли.
11. Соединение по п.9, где терапия направлена на желудочно-кишечные расстройства.
12. Соединение по п.9, где терапия направлена на повреждения спинного мозга.
13. Соединение по п.9, где терапия направлена на расстройства симпатической нервной системы.
14. Применение соединения формулы I по п.1 для производства лекарства для применения при лечении боли.
15. Применение соединения формулы I по п.1 для производства лекарства для применения при лечении желудочно-кишечных расстройств.
16. Применение соединения формулы I по п.1 для производства лекарства для применения при лечении повреждений спинного мозга.
17. Фармацевтическая композиция, содержащая соединение формулы I по п.1 в качестве активного ингредиента вместе с фармакологически и фармацевтически приемлемым носителем.
18. Способ лечения боли, при котором субъекту, нуждающемуся в устранении боли, вводят эффективное количество соединения формулы I по п.1.
19. Способ лечения желудочно-кишечных расстройств, при котором субъекту, страдающему указанным желудочно-кишечным расстройством, вводят эффективное количество соединения формулы I по п.1.
20. Способ лечения повреждений спинного мозга, при котором субъекту, страдающему указанным повреждением спинного мозга, вводят эффективное количество соединения формулы I по п.1.
RU2002114345/04A 1999-12-20 2000-12-15 4-(пиперазинил(8-хинолинил)метил)бензамиды, фармацевтическая композиция и способ лечения боли RU2260006C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904673-2 1999-12-20
SE9904673A SE9904673D0 (sv) 1999-12-20 1999-12-20 Novel compounds

Publications (2)

Publication Number Publication Date
RU2002114345A true RU2002114345A (ru) 2004-01-10
RU2260006C2 RU2260006C2 (ru) 2005-09-10

Family

ID=20418209

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002114345/04A RU2260006C2 (ru) 1999-12-20 2000-12-15 4-(пиперазинил(8-хинолинил)метил)бензамиды, фармацевтическая композиция и способ лечения боли

Country Status (34)

Country Link
US (1) US6784181B2 (ru)
EP (1) EP1242402B1 (ru)
JP (1) JP2003518022A (ru)
KR (1) KR100807515B1 (ru)
CN (1) CN1225465C (ru)
AT (1) ATE254120T1 (ru)
AU (1) AU780714B2 (ru)
BG (1) BG65456B1 (ru)
BR (1) BR0016578A (ru)
CA (1) CA2393568C (ru)
CO (1) CO5271646A1 (ru)
CZ (1) CZ20022122A3 (ru)
DE (1) DE60006583T2 (ru)
DK (1) DK1242402T3 (ru)
EE (1) EE05035B1 (ru)
ES (1) ES2210028T3 (ru)
HK (1) HK1048113B (ru)
HU (1) HUP0300298A2 (ru)
IL (2) IL150126A0 (ru)
IS (1) IS2194B (ru)
MX (1) MXPA02006062A (ru)
MY (1) MY125394A (ru)
NO (1) NO323402B1 (ru)
NZ (1) NZ519985A (ru)
PL (1) PL356797A1 (ru)
PT (1) PT1242402E (ru)
RU (1) RU2260006C2 (ru)
SE (1) SE9904673D0 (ru)
SK (1) SK285753B6 (ru)
TR (1) TR200400237T4 (ru)
TW (1) TWI238822B (ru)
UA (1) UA72945C2 (ru)
WO (1) WO2001045637A2 (ru)
ZA (1) ZA200204256B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987736B2 (en) * 2000-07-10 2015-03-24 Amit Goyal [100] or [110] aligned, semiconductor-based, large-area, flexible, electronic devices
SE0100764D0 (sv) * 2001-03-07 2001-03-07 Astrazeneca Ab New assymetric process
CA2446326C (en) 2001-05-18 2010-12-07 Astrazeneca Ab 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
US7030124B2 (en) * 2001-10-29 2006-04-18 Ardent Pharmaceuticals, Inc. Method of treating depression with delta receptor agonist compounds
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203302D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203303D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0400027D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
MX2007001240A (es) 2004-08-02 2007-03-23 Astrazeneca Ab Derivados de diarilmetil-piperazina, preparaciones y usos de las mismas.
SE0401968D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
WO2007137417A1 (en) * 2006-05-26 2007-12-06 Neuromed Pharmaceuticals Ltd. Heterocyclic compounds as calcium channel blockers
MY148880A (en) * 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
CA2724955A1 (en) * 2008-05-20 2009-11-26 Astrazeneca Ab Method of treating anxious major depressive disorder
EP3725815B1 (en) * 2017-12-12 2022-10-05 Tokyo University of Science Foundation Active energy ray-curable composition

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH585209A5 (ru) 1973-06-29 1977-02-28 Cermol Sa
DE2900810A1 (de) 1979-01-11 1980-07-24 Cassella Ag Substituierte n-benzhydryl-n'-p- hydroxybenzyl-piperazine und verfahren zu ihrer herstellung
IT1140978B (it) 1980-05-23 1986-10-10 Selvi & C Spa 1-(4-clorobenzidril)-4-(2,3-diidros sipropil)-piperazina, metodi per la sua preparazione e relative composizione farmaceutiche
GB8320701D0 (en) 1983-08-01 1983-09-01 Wellcome Found Chemotherapeutic agent
IT1196150B (it) 1984-06-19 1988-11-10 Poli Ind Chimica Spa Derivati di 1-(bis-(4-fluorofenil)metil)-4-(3-fenil-2-propenil)-esaidro-1h-1,4-diazepina ad attivita' calcio antagonista,sua preparazione e composizioni che lo contengono
SE8500573D0 (sv) 1985-02-08 1985-02-08 Ferrosan Ab Novel piperazinecarboxamides having a phenoxyalkyl or thiophenoxyalkyl side chain
US5028610A (en) 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
US4829065A (en) 1987-04-24 1989-05-09 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
US4826844A (en) 1987-09-30 1989-05-02 American Home Products Corporation Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols
RU2093156C1 (ru) 1989-11-22 1997-10-20 Жансен Фармасетика Н.В. L-(-)-2-(аминокарбонил)-n-(4-амино-2,6-дихлорфенил-4[5,5-бис(4-фторфенил)пентил]-1-пиперазинацетамид, его фармацевтически приемлемая кислотно-аддитивная соль или гидрат, способ его получения и средство для хранения сердца донора
US5807858A (en) 1996-06-05 1998-09-15 Delta Pharmaceutical, Inc. Compositions and methods for reducing respiratory depression
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5681830A (en) 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
US5574159A (en) 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
FR2696744B1 (fr) 1992-10-12 1994-12-30 Logeais Labor Jacques Dérivés de 2-pyrrolidone, leur procédé de préparation et leurs applications en thérapeutique.
RU2133744C1 (ru) 1993-07-30 1999-07-27 Дельта Фармасьютикалз, Инк. Пиперазиновые соединения
JP3352184B2 (ja) 1993-11-12 2002-12-03 株式会社アズウェル ピペラジン不飽和脂肪酸誘導体
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9604786D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
AU2009799A (en) 1997-12-24 1999-07-19 Ortho-Mcneil Pharmaceutical, Inc. 4-(aryl(piperidin-4-yl)) aminobenzamides which bind to the delta-opioid receptor

Also Published As

Publication number Publication date
DK1242402T3 (da) 2004-03-01
DE60006583T2 (de) 2004-09-30
KR20020067919A (ko) 2002-08-24
DE60006583D1 (de) 2003-12-18
AU2564301A (en) 2001-07-03
EP1242402B1 (en) 2003-11-12
MXPA02006062A (es) 2002-12-05
SK8852002A3 (en) 2003-05-02
WO2001045637A2 (en) 2001-06-28
KR100807515B1 (ko) 2008-02-26
PT1242402E (pt) 2004-03-31
RU2260006C2 (ru) 2005-09-10
CA2393568C (en) 2009-08-18
BG106806A (en) 2003-03-31
HK1048113A1 (en) 2003-03-21
ES2210028T3 (es) 2004-07-01
WO2001045637A3 (en) 2001-12-13
BG65456B1 (bg) 2008-08-29
HK1048113B (zh) 2004-04-30
US20030119845A1 (en) 2003-06-26
TR200400237T4 (tr) 2004-04-21
NZ519985A (en) 2004-05-28
IL150126A (en) 2008-06-05
US6784181B2 (en) 2004-08-31
CN1225465C (zh) 2005-11-02
NO20022918L (no) 2002-08-02
CZ20022122A3 (cs) 2002-11-13
MY125394A (en) 2006-07-31
NO20022918D0 (no) 2002-06-18
IL150126A0 (en) 2002-12-01
IS2194B (is) 2007-01-15
PL356797A1 (en) 2004-07-12
EE200200334A (et) 2003-10-15
AU780714B2 (en) 2005-04-14
ZA200204256B (en) 2003-08-28
CO5271646A1 (es) 2003-04-30
NO323402B1 (no) 2007-04-23
CA2393568A1 (en) 2001-06-28
EP1242402A2 (en) 2002-09-25
EE05035B1 (et) 2008-06-16
IS6423A (is) 2002-06-14
ATE254120T1 (de) 2003-11-15
JP2003518022A (ja) 2003-06-03
HUP0300298A2 (hu) 2003-06-28
TWI238822B (en) 2005-09-01
BR0016578A (pt) 2002-09-24
UA72945C2 (ru) 2005-05-16
SE9904673D0 (sv) 1999-12-20
CN1434816A (zh) 2003-08-06
SK285753B6 (sk) 2007-07-06

Similar Documents

Publication Publication Date Title
RU2003131964A (ru) Производные 4-(фенил-пиперазинил-метил)-бензамида и их применение для лечения боли, тревоги или желудочно-кишечных расстройств
RU2002114345A (ru) Новые 4-(пиперазинил(8-хинолинил)метил)бензамиды
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
RU2002114343A (ru) Новые соединения
RU2368604C2 (ru) Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина
JP2006504656A5 (ru)
RU98113786A (ru) Новые соединения, обладающие анальгезирующим действием
RU2002123350A (ru) Дипептиднитрильные ингибиторы катепсина К
RU2003129502A (ru) Соединение, фармацевтическая композиция, применение, способ предупреждения или лечения заболеваний
JP2009503107A5 (ru)
CA2361057A1 (en) Quinoline derivatives and quinazoline derivatives
JP2003518022A5 (ru)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2008110984A5 (ru)
JP2003528872A5 (ru)
JP2005508293A5 (ru)
RU2004107854A (ru) Производные 4[пиперидин-4-илиден-(3-карбомоилфенил)метил]бензамида и их применение для лечении боли, спинальных повреждений или желудочно-кишечных расстройств
RU2002103302A (ru) Производные N-(Индолкарбонил)пиперазина
RU2003131970A (ru) Производные 4-(фенил-пиперидин-4-илиден-метил)-бензамида и их применение для лечения боли, тревоги или желудочно-кишечных расстройств
CA2660529A1 (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
KR920021541A (ko) 벤조푸란 유도체
RU2018112993A (ru) Соединения и способы для ингибирования JAK
JP2006508987A5 (ru)
RU2394031C2 (ru) Соли четвертичного аммония в качестве антагонистов м3
RU2017141561A (ru) Производные тетрагидронафтиридинилпропионовой кислоты и их применение

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20081216